AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16782975
Drug: Propofol 3-5
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 3-5 mg kg(‐1) h(‐1)
Trial: 10923605
Drug: Topical nasal
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nasal azelastine (two sprays BID)
Trial: 8833208
Drug: Alendronate 20
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate 20 mg/day for 2 years followed by 5 mg/day for the 3rd year
Trial: 3911964
Drug: Suprofen 300
RxNorm normalized name: Suprofen
DrugBank: Suprofen (DB00870)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suprofen 300 mg suppositories
Trial: 20219110
Drug: Pneumococcal polysaccharide
RxNorm normalized name: pneumococcal polysaccharides (23)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal polysaccharide vaccine (PPV)
Trial: 28679552
Drug: High-fiber diet
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber diet (≥18 g NSP/d)
Trial: 11349017
Drug: Placebo-vaccine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-vaccine plus 25 microg of LT(R192G)
Trial: 11349017
Drug: Placebo-vaccine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-vaccine plus placebo-adjuvant
Trial: 8997460
Drug: Intramuscular meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular meperidine (0.75 mg/kg) at gluteal site
Trial: 8997460
Drug: Intramuscular meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular meperidine (0.75 mg/kg) at deltoid site
Trial: 8997460
Drug: Both injection
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both injection sites (gluteal and deltoid)
Trial: 7700051
Drug: Mild subgroup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild subgroup (patients receiving conservative treatment of thrombectomy)
Trial: 29664983
Drug: Ranibizumab (Lucentis;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (Lucentis; Genentech) monotherapy
Trial: 29664983
Drug: Ranibizumab plus
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab plus peripheral laser (combination therapy)
Trial: 26386793
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg/d (5 mg/d for patients ≥75 years and/or <60 kg)
Trial: 23130135
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/d
Trial: 17159259
Drug: He-Ne laser
RxNorm normalized name: Ne
DrugBank: Neon (DB11589)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: He-Ne laser therapy (wavelength 632.8 nm, output 10mW)
Trial: 17159259
Drug: Oral analgesics,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral analgesics, local application of anaesthetics, 0.9% saline, and povidine wash
Trial: 10862636
Drug: Isosorbide 5
RxNorm normalized name: Isosorbide 5-nitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide 5 mononitrate (40 mg)
Trial: 9043272
Drug: J-pouch irrigations
RxNorm normalized name: hydroxypropyl cellulose (type J)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: J-pouch irrigations through the efferent ileostomy stoma, daily for 4 weeks.
Trial: 1574953
Drug: Thyrotropin-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin-releasing hormone (400 micrograms iv)
Trial: 2862223
Drug: Adjuvant oophorectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant oophorectomy followed by chemotherapy with cyclophosphamide, methotrexate, 5‐fluorouracil, and prednisone (CMFp)
Trial: 2862223
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with cyclophosphamide, methotrexate, 5‐fluorouracil, and prednisone (CMFp) alone
Trial: 2668051
Drug: Fructose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (50 g)
Trial: 30529886
Drug: Sucralose (0.33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralose (0.33 g)
Trial: 30529886
Drug: Control (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (300 mL plain tap water)
Trial: 27146650
Drug: Montmorency tart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montmorency tart cherry (MC) juice (60 mL)
Trial: 24963007
Drug: Implantable cardioverter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantable cardioverter defibrillator therapy (control)
Trial: 20105186
Drug: Oxandrolone (Ox)
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxandrolone (Ox) 0.03 mg/kg per day
Trial: 20105186
Drug: Oxandrolone (Ox)
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxandrolone (Ox) 0.06 mg/kg per day
Trial: 15936184
Drug: Formoterol/budesonide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol/budesonide combination 9/320 microg
Trial: 29162214
Drug: Rosuvastatin/ezetimibe fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin/ezetimibe fixed-dose combination (FDC; 10 mg/10 mg)
Trial: 29162214
Drug: Rosuvastatin/ezetimibe single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin/ezetimibe single agents (10 mg/10 mg)
Trial: 9094892
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (294 mg vitamin E, 1000 mg vitamin C, and 60 mg ubiquinone daily)
Trial: 31184796
Drug: Open-ended group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-ended group intervention based on a cognitive behavioural therapy for insomnia self-help book
Trial: 31184796
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of the book and the open-ended group intervention
Trial: 18318773
Drug: Udenafil 50
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil 50 mg
Trial: 18162935
Drug: Killed oral
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Killed oral cholera vaccine (mass immunization of older children and adults)
Trial: 18162935
Drug: Vaccine coverage
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine coverage of adult women
Trial: 7477166
Drug: Triiodothyronine (liothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triiodothyronine (liothyronine sodium) administered as an intravenous bolus of 0.8 microgram per kilogram of body weight and then as an infusion of 0.113 microgram per kilogram per hour for six hours
Trial: 2401187
Drug: Lornoxicam (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (4 mg as a film-coated tablet) alone
Trial: 2401187
Drug: Maalox (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maalox (10 ml)
Trial: 2401187
Drug: Solugastril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solugastril (10 g)
Trial: 6381007
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) at 1.00 +/- 0.06 U insulin/h from 10 p.m. to 8 a.m.
Trial: 6381007
Drug: Interruption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interruption of insulin infusion between 11 p.m. and 1 a.m.
Trial: 28857811
Drug: Urinary biomarker‐triggered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary biomarker‐triggered KDIGO care bundle (early optimization of fluid status, maintenance of perfusion pressure, discontinuation of nephrotoxic agents)
Trial: 27788811
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (50 mg/kg) administered in the last 30 minutes of the operation.
Trial: 20055981
Drug: Carboplatin plus
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin plus paclitaxel (CP) - carboplatin AUC5 + paclitaxel 175 mg/m2, d1q21
Trial: 20055981
Drug: Carboplatin plus
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin plus pegylated liposomal doxorubicin (CLD) - carboplatin AUC5 + pegylated LD 45 mg/m2, d1q28
Trial: 12566175
Drug: L-365,260 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-365,260 30 mg
Trial: 12566175
Drug: L-365,260 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-365,260 120 mg
Trial: 3907395
Drug: Enprofylline 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline 1.5 mg/kg b.wt.
Trial: 3907395
Drug: Theophylline 5
RxNorm normalized name: theophylline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 5 mg/kg b.wt.
Trial: 30314913
Drug: two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two doses of 9vHPV
Trial: 27622956
Drug: Iontophoretic SM
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoretic SM injection
Trial: 20051587
Drug: Tramadol Contramid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol Contramid OAD 200-mg tablets
Trial: 20051587
Drug: tramadol IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tramadol IR 50-mg tablets
Trial: 18719632
Drug: CM3 (six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM3 (six capsules taken 30 min before a standardized solid meal)
Trial: 15813665
Drug: Salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone propionate 50/100 microg twice daily
Trial: 15813665
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 100 microg twice daily plus oral montelukast 10mg daily
Trial: 8971297
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg topical pharyngeal lidocaine spray
Trial: 8971297
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg topical pharyngeal lidocaine spray
Trial: 28500254
Drug: Dabigatran (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (110 mg BID for normal renal function, 75 mg BID for impaired renal function)
Trial: 21447137
Drug: Buccal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal infiltration of 1.8 mL of 4% articaine with 1:100,000 epinephrine
Trial: 21447137
Drug: Lingual infiltration
RxNorm normalized name: Nitroglycerin Lingual Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lingual infiltration of 1.8 mL of 4% articaine with 1:100,000 epinephrine
Trial: 21447137
Drug: Buccal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal infiltration
Trial: 19004194
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at bilateral Hegu (LI 4) plus intravenous dripping of oxytocin
Trial: 19004194
Drug: Intravenous dripping
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dripping of oxytocin
Trial: 10795744
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg QAM
Trial: 10795744
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg QAM
Trial: 10795744
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg QAM
Trial: 1740204
Drug: Protocol B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B (GnRH agonist)
Trial: 20137647
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy + surgical resection (CS group)
Trial: 9531580
Drug: low-dose IFN-alpha2b
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose IFN-alpha2b (3 MIU, 5 days/week)
Trial: 8554248
Drug: Vitamin D3,
RxNorm normalized name: Vitamin D3, 25 mcg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3, 400 IU in one tablet daily
Trial: 19370185
Drug: Nimulid (N)
RxNorm normalized name: N-6022
DrugBank: N-6022 (DB12206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimulid (N) 100 mg 2 x/day for 20 days
Trial: 19370185
Drug: Tenaprost (T)
RxNorm normalized name: beraprost
DrugBank: Beraprost (DB05229)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenaprost (T) 100 mg 2 x/day for 20 days
Trial: 16443872
Drug: Model Predictive
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model Predictive Control (MPC) algorithm (n = 30, target range 80-110 mg/dl)
Trial: 11780205
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (donors without G-CSF)
Trial: 9663838
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg o.m., clarithromycin 250 mg b.d. and amoxycillin 500 mg b.d. (OAC)
Trial: 9663838
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg o.m., metronidazole 400 mg b.d. and clarithromycin 250 mg b.d. (OMC)
Trial: 2859781
Drug: Acebutolol with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol with diuretic
Trial: 2859781
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with diuretic
Trial: 27085565
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C intervention (1,000 mg every other day)
Trial: 24641937
Drug: Intensified chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified chemotherapy (GFFC) + Enoxaparin (40 mg daily)
Trial: 16037104
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist ganirelix daily (0.25 mg each, n = 37)
Trial: 16037104
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist ganirelix every other day (0.25 mg each, n = 36)
Trial: 12351376
Drug: Idarubicin 10
RxNorm normalized name: IDArubicin 10 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin 10 mg/m(2) (group 2A)
Trial: 12351376
Drug: Idarubicin 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin 12 mg/m(2) (group 2B)
Trial: 8847094
Drug: Ragweed allergen
RxNorm normalized name: ALLERGENIC EXTRACT, SHORT RAGWEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ragweed allergen (RWA) treatment of sera
Trial: 2187700
Drug: Almitrine 50
RxNorm normalized name: almitrine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine 50 mg b.d. p.o.
Trial: 30711416
Drug: CCZ (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCZ (75 mg twice daily)
Trial: 30711416
Drug: CCZ+RBV (1000/1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCZ+RBV (1000/1200 mg daily)
Trial: 19141125
Drug: Basiliximab (Simulect)
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab (Simulect) administration
Trial: 19141125
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (recipients without basiliximab injection)
Trial: 18184535
Drug: d‐MPH bimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐MPH bimodal release formulation (20 mg)
Trial: 18184535
Drug: d‐MPH immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐MPH immediate release formulation (two 10 mg doses given 4 h apart)
Trial: 18184535
Drug: d,l‐MPH bimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d,l‐MPH bimodal release formulation (40 mg)
Trial: 7993707
Drug: Antiphospholipid antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiphospholipid antibodies (aPL)
Trial: 3251497
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of sustained release PPA
Trial: 30698069
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment (radiotherapy for endometrial cancer)
Trial: 30698069
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment (chemotherapy for ovarian cancer)
Trial: 30698069
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy or early-stage disease
Trial: 30698069
Drug: Clinical characteristics
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical characteristics (comorbidities, treatment, tumor stage)
Trial: 26429700
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment with dihydroartemisinin‐piperaquine
Trial: 26429700
Drug: Intermittent screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent screening and treatment with dihydroartemisinin‐piperaquine
Trial: 21199881
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment with sulfadoxine‐pyrimethamine
Trial: 21148051
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + AICAR (67 mg·kg(‐1))
Trial: 21148051
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + placebo (saline)
Trial: 16904415
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (20 microg of ethinylestradiol (EE)/100 microg of levonorgestrel)
Trial: 16904415
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (15 microg of EE/60 microg of gestodene)
Trial: 16904415
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (combined oral contraceptives and vaginal ring)
Trial: 12829654
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training (heart rate‐controlled endurance training twice a week and supervised muscle strength training twice a week for 12 months)
Trial: 6116723
Drug: Gonococcal pilus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonococcal pilus vaccine
Trial: 1701817
Drug: Preexisting antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preexisting antibodies
Trial: 6514179
Drug: Diazepam (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (8 mg)
Trial: 31145207
Drug: Topical insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical insulin (TI) 1 unit/drop 4 times per day for 4 weeks
Trial: 31145207
Drug: Topical insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical insulin (TI)
Trial: 30522397
Drug: Homemade street
RxNorm normalized name: Welmedix Homecare Pro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homemade street foods (e.g., fried cakes, stewed meat/fish/liver dishes)
Trial: 26436491
Drug: TORS plus
RxNorm normalized name: Lipo Factors Plus B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TORS plus adjuvant therapy
Trial: 25152982
Drug: 36 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 36 weeks PEG‐RBV therapy (group B)
Trial: 25152982
Drug: 48 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48 weeks PEG‐RBV therapy (group A)
Trial: 21112054
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol 400 μg 3 hours before MVA
Trial: 21112054
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol 400 μg 3 hours before EVA
Trial: 19158210
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation of 125 mg FeSO4 daily from 10 weeks to 9 months postpartum (IDA-Fe)
Trial: 1130879
Drug: Intraluminal 5
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraluminal 5 FU (30mg/kg) with intravenous 5 FU (10mg/kg) on the first two postoperative days and 5 subsequent postoperative courses of oral 5 FU (90 mg/kg in each 18 day course) over one year period.